Gurtner aymone (58 risultati)

Condizione: New. pp. 52.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Condizione: New.

Paperback. Condizione: Brand New. 52 pages. 8.66x5.91x0.12 inches. In Stock.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Taschenbuch. Condizione: Neu. Inhibition of microRNA biogenesis by mutant p53 in cancer | The gain of function of mutant p53 passes through Drosha | Aymone Gurtner (u. a.) | Taschenbuch | 52 S. | Englisch | 2017 | Scholars' Press | EAN 9783659843358 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. …

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Condizione: New.

Condizione: New.

Condizione: New.

Condizione: New.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Colorectal cancer (CRC) is one of the major leading causes of cancer-related death. CRC development and progression involves mutational events in oncogenes and tumor suppressor genes such as p53. Of note mutant p53 proteins can acquire novel oncogenic functions known as gain of function activities (GOF) favouring in vivo tumour induction. microRNAs are potent regulators of gene expression. Deregulation of microRNAs expression has been found in various cancer types among which CRC, thus, miRNAs may be potential targets for cancer therapy. Our experimental efforts have provided substantial advances in understanding the molecular mechanism by which mutant p53, to inactivate tumor suppressive pathways driven by oncosuppressor microRNAs, globally inhibits microRNA biogenesis in cancer by interfering with Drosha, a key regulator of microRNA biogenesis. Our study will impact on the knowledge of the molecular mechanisms through which mutant p53 exerts its GOF activities, and regulates gene expression, by adding to this puzzle the ability to interfere with miRNA processing. Moreover, the identification of oncosuppressor miRNAs will be relevant to the diagnosis and treatment of cancer. 52 pp. Englisch.…

Condizione: New. Print on Demand pp. 52.

Paperback. Condizione: new. Paperback. Le cancer colorectal (CCR) est l'une des principales causes de deces lies au cancer. Le developpement et la progression du CCR impliquent des evenements mutationnels au niveau des oncogenes et des genes suppresseurs de tumeurs tels que le gene p53. Il convient de noter que les proteines p53 mutantes peuvent acquerir de nouvelles fonctions oncogeniques, appelees gains de fonction (GOF), favorisant l'induction tumorale in vivo. Les microARN sont de puissants regulateurs de l'expression genique. Une deregulation de l'expression des microARN a ete observee dans divers types de cancers, dont le CCR; les miARN pourraient donc constituer des cibles potentielles pour le traitement du cancer. Nos travaux experimentaux ont permis des avancees substantielles dans la comprehension du mecanisme moleculaire par lequel la proteine p53 mutante, afin d'inactiver les voies de suppression tumorale regulees par les microARN oncosuppresseurs, inhibe globalement la biogenese des microARN dans le cancer en interferant avec Drosha, un regulateur cle de la biogenese des microARN. Notre etude apportera un eclairage sur les mecanismes moleculaires par lesquels la proteine p53 mutante exerce ses activites de gain de fonction (GOF) et regule l'expression genique, en ajoutant a ce puzzle sa capacite a interferer avec le traitement des miARN.De plus, l'identification des miARN oncosuppresseurs sera pertinente pour le diagnostic et le traitement du cancer. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Condizione: New. PRINT ON DEMAND pp. 52.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware 56 pp. Spanisch.

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Gurtner AymoneAymone Gurtner is a research scientist in the field of molecular oncology, author of 27 scientific papers. She hold a specialization in Applied Biotechnology and a PhD in Genetics and Cell Biology. Her co-author Frances.…

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Colorectal cancer (CRC) is one of the major leading causes of cancer-related death. CRC development and progression involves mutational events in oncogenes and tumor suppressor genes such as p53. Of note mutant p53 proteins can acquire novel oncogenic functions known as gain of function activities (GOF) favouring in vivo tumour induction. microRNAs are potent regulators of gene expression. Deregulation of microRNAs expression has been found in various cancer types among which CRC, thus, miRNAs may be potential targets for cancer therapy. Our experimental efforts have provided substantial advances in understanding the molecular mechanism by which mutant p53, to inactivate tumor suppressive pathways driven by oncosuppressor microRNAs, globally inhibits microRNA biogenesis in cancer by interfering with Drosha, a key regulator of microRNA biogenesis. Our study will impact on the knowledge of the molecular mechanisms through which mutant p53 exerts its GOF activities, and regulates gene expression, by adding to this puzzle the ability to interfere with miRNA processing. Moreover, the identification of oncosuppressor miRNAs will be relevant to the diagnosis and treatment of cancer.…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Colorectal cancer (CRC) is one of the major leading causes of cancer-related death. CRC development and progression involves mutational events in oncogenes and tumor suppressor genes such as p53. Of note mutant p53 proteins can acquire novel oncogenic functions known as gain of function activities (GOF) favouring in vivo tumour induction. microRNAs are potent regulators of gene expression. Deregulation of microRNAs expression has been found in various cancer types among which CRC, thus, miRNAs may be potential targets for cancer therapy. Our experimental efforts have provided substantial advances in understanding the molecular mechanism by which mutant p53, to inactivate tumor suppressive pathways driven by oncosuppressor microRNAs, globally inhibits microRNA biogenesis in cancer by interfering with Drosha, a key regulator of microRNA biogenesis. Our study will impact on the knowledge of the molecular mechanisms through which mutant p53 exerts its GOF activities, and regulates gene expression, by adding to this puzzle the ability to interfere with miRNA processing. Moreover, the identification of oncosuppressor miRNAs will be relevant to the diagnosis and treatment of cancer.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 52 pp. Englisch.…

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - El cáncer colorrectal (CCR) es una de las principales causas de muerte relacionada con el cáncer. El desarrollo y la progresión del CCR implican eventos mutacionales en oncogenes y genes supresores de tumores, como el p53. Cabe destacar que las proteínas p53 mutantes pueden adquirir nuevas funciones oncogénicas, conocidas como actividades de ganancia de función (GOF), que favorecen la inducción tumoral in vivo. Los microARN son potentes reguladores de la expresión génica. Se ha observado una desregulación de la expresión de los microARN en diversos tipos de cáncer, entre ellos el CCR; por lo tanto, los microARN pueden constituir dianas potenciales para la terapia oncológica. Nuestros trabajos experimentales han aportado avances sustanciales en la comprensión del mecanismo molecular por el cual el p53 mutante, para inactivar las vías supresoras de tumores impulsadas por microARN oncosupresores, inhibe de forma global la biogénesis de los microARN en el cáncer al interferir con Drosha, un regulador clave de dicha biogénesis. Nuestro estudio contribuirá al conocimiento de los mecanismos moleculares a través de los cuales la proteína p53 mutante ejerce sus actividades de ganancia de función (GOF) y regula la expresión génica, al añadir a este rompecabezas la capacidad de interferir en el procesamiento de los miARN. Además, la identificación de miARN oncosupresores será relevante para el diagnóstico y el tratamiento del cáncer.…

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware 56 pp. Französisch.

Paperback. Condizione: new. Paperback. Il carcinoma colorettale (CRC) e una delle principali cause di morte per tumore. Lo sviluppo e la progressione del CRC comportano eventi mutazionali a carico degli oncogeni e dei geni oncosoppressori, come il p53. E importante sottolineare che le proteine p53 mutanti possono acquisire nuove funzioni oncogeniche, note come attivita di "guadagno di funzione" (GOF), che favoriscono l'induzione tumorale in vivo. I microRNA sono potenti regolatori dell'espressione genica. E stata riscontrata una deregolazione dell'espressione dei microRNA in vari tipi di tumore, tra cui il CRC; pertanto, i miRNA potrebbero rappresentare potenziali bersagli per la terapia antitumorale. Il nostro lavoro sperimentale ha consentito progressi sostanziali nella comprensione del meccanismo molecolare attraverso il quale il p53 mutante, al fine di inattivare le vie di soppressione tumorale guidate dai microRNA oncosoppressori, inibisce globalmente la biogenesi dei microRNA nel tumore interferendo con Drosha, un regolatore chiave della biogenesi dei microRNA. Il nostro studio contribuira alla comprensione dei meccanismi molecolari attraverso i quali la proteina p53 mutante esercita le sue attivita di guadagno di funzione (GOF) e regola l'espressione genica, aggiungendo a questo quadro la capacita di interferire con l'elaborazione dei miRNA. Inoltre, l'identificazione dei miRNA oncosoppressori sara rilevante per la diagnosi e il trattamento del cancro. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Paperback. Condizione: new. Paperback. Rak jelita grubego (CRC) jest jedna z glownych przyczyn zgonow zwiazanych z nowotworami. Powstawanie i progresja CRC wiaze sie z mutacjami w genach onkogennych oraz genach supresorowych nowotworow, takich jak p53. Warto zauwazyc, ze zmutowane bialka p53 moga nabywac nowe funkcje onkogenne, znane jako aktywnosc typu "zysk funkcji" (GOF), sprzyjajace indukcji nowotworu in vivo. MikroRNA sa silnymi regulatorami ekspresji genow. Zaburzenia ekspresji mikroRNA stwierdzono w roznych typach nowotworow, w tym w CRC, dlatego miRNA moga stanowic potencjalne cele terapii onkologicznej. Nasze badania eksperymentalne przyniosly znaczacy postep w zrozumieniu mechanizmu molekularnego, dzieki ktoremu zmutowane p53, w celu dezaktywacji szlakow supresji nowotworowej regulowanych przez mikroRNA o dzialaniu onkosupresorowym, globalnie hamuje biogeneze mikroRNA w nowotworze poprzez zaklocanie dzialania Drosha - kluczowego regulatora biogenezy mikroRNA. Nasze badania wplyna na stan wiedzy dotyczacej mechanizmow molekularnych, poprzez ktore zmutowany p53 wywiera swoje dzialanie typu "gain-of-function" (GOF) i reguluje ekspresje genow, uzupelniajac te ukladanke o zdolnosc do zaklocania przetwarzania mikroRNA. Ponadto identyfikacja mikroRNA o dzialaniu onkosupresorowym bedzie miala znaczenie dla diagnostyki i leczenia nowotworow. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…